Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06493968

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Placenta Accreta Spectrum Female Urogenital Diseases and Pregnancy Complications Obstetric Labor Complications Placenta Accreta Placenta Diseases Pregnancy Complications Urogenital Diseases

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnancy of singleton living fetus
  • Previous one or more cesarean sections
  • Gestational age: > 32 weeks
  • The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity".
  • Preoperative hemoglobin more than 10 gm/dl
  • Cases with PAS that will undergoing CS Hysterectomy

Exclusion criteria

  • Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.….
  • Any known or reported hypersensitivity to the used medication.
  • All cases with spontaneous placental separation at laparotomy.
  • All patients undergoing conservative management of PAS.
  • All cases which necessitate emergency termination.

Treatment and study plan

Oxytocin

Drug

Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision

Placebo

Other

IV bolus of normal saline immediately with the uterine incision

Primary outcomes

  1. Intraoperative blood loss

    Time frame: during operation

    amount of intraoperative blood loss in patients with PAS disorders undergoing cesarean hysterectomy

Secondary outcomes

  1. operative time

    Time frame: during operation

Study contacts

Contact information is provided by the study sponsor or research team.

Abdalla Mousa

CONTACT

[email protected]

+201277664430

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With Placenta Accrete Spectrum Disorders Undergoing Cesarean Hysterectomy

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jul 10, 2024
Registry last updated
Jul 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.